Abstract |
Cyclin-dependent kinase (CDK) inhibitors represent a new form of cytotoxic chemotherapy. Advanced practitioners can read this article to find out about the science behind CDK inhibition, when CDKs are indicated, how to monitor for and manage side effects, as well as when and how to dose adjust.
|
Authors | Lee S Schwartzberg, Heather R Greene |
Journal | Journal of the advanced practitioner in oncology
(J Adv Pract Oncol)
Vol. 8
Issue 3
Pg. 250-254
(Apr 2017)
ISSN: 2150-0878 [Print] United States |
PMID | 29928547
(Publication Type: Journal Article, Review)
|